Alnylam Pharmaceuticals, Inc. (ALNY) financial statements and ratios from SEC XBRL: revenue $4.2B (TTM), net margin 8.4%, revenue growth 65.2% YoY, P/E 108.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $3.71B |
| Revenue (TTM) | $4.2B |
| Net Margin | 8.4% |
| Operating Margin (TTM) | 17.7% |
| Revenue Growth (YoY) | 65.2% |
| EPS Growth (YoY) | -209.6% |
| FCF Growth (YoY) | -1192.7% |
| P/E Ratio | 108.0 |
| EV / EBITDA | 42.6 |
| Price / Book | 23.28 |
| Price / Sales | 8.07 |
| FCF Yield | 2.2% |
| Altman Z-Score | 4.31 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ALNY overview · ALNY earnings · ALNY KPIs · ALNY documents · ALNY ownership · ALNY peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.